Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atossa Therapeutics (DE:YAG2)
FRANKFURT:YAG2
Atossa Therapeutics (YAG2) Stock Price & Analysis
1 Followers
YAG2 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.54 - €2.14
Previous Close€1.25
Volume0.00
Average Volume (3M)6.01K
Market Cap
€167.56M
Enterprise Value€84.24M
Total Cash (Recent Filing)$88.46M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta1.07
Next Earnings
May 14, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding125,304,064
10 Day Avg. Volume1,347
30 Day Avg. Volume6,014
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.12
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.80
Forecast
1Y Price Target
€3.77Price Target Upside202.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Atossa Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
YAG2 FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was €0.54 and its highest was €2.13 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Currently, no data Available
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is May 14, 2024 which is in 18 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on Apr 01, 2024. The company reported -€0.057 earnings per share for the quarter, beating the consensus estimate of -€0.061 by €0.005.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atossa Therapeutics have?
Currently, no data Available
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -€0.057 in its last earnings report, beating expectations of -€0.061. Following the earnings report the stock price went down -6.935%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Among the largest hedge funds holding Atossa Therapeutics’s share is Graham Capital Management, L.P.. It holds Atossa Therapeutics’s shares valued at N/A.
---
Atossa Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€3.77 (202.32% Upside)
€3.77 (202.32% Upside)
Blogger Sentiment
Bullish
DE:YAG2 Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $44.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.43%
12-Months-Change
Fundamentals
Return on Equity
-28.80%
Trailing 12-Months
Asset Growth
-22.08%
Trailing 12-Months
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
---
YAG2 Earnings Call
Q2 2023
0:00 / 0:00
---
YAG2 Stock 12 Months Forecast
Average Price Target
€3.77
▲(202.32% Upside)
Technical Analysis
Atossa Therapeutics
―
Benitec Biopharma
―
Anavex Life Sciences
―
Eton Pharmaceuticals
―
Traws Pharma
―
Best Analysts Covering YAG2
1 Year
1 Year Success Rate
8/9 ratings generated profit
1 Year Average Return
+44.39%
reiterated a buy rating 18 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +44.39% per trade.
---